THE BELGIAN OPHTHALMIC ASSOCIATIONS
Abstract bekijken
Deze abstract is toegekend aan sessie Poster session in O'Bistro
| Titel | Therapeutic potential of placental growth factor (PlGF) inhibition in scar formation after glaucoma filtration surgery |
| Doel | We checked the hypothesis that placental growth factor (PlGF) may be a target for improvement of the outcome of glaucoma filtration surgery (GFS). |
| Methodes | The effect of the anti-murine PlGF-antibody (5D11D4) was investigated in a mouse model of GFS. Immediately after surgery 5D11D4 (5.2µg) or 1C8, an irrelevant mouse IgG antibody (4.8 µl), was injected in the anterior chamber (n=10 eyes for both groups). An anti-murine VEGF-R2 antibody (DC101) was used as a positive control (6.2 µg; n=10). Mice were killed on post-operative day 8. Treatment outcome was studied by clinical investigation of the bleb and by immunohistological stainings. All antibodies were kindly provided by ThromboGenics NV. |
| Resultaten | Treatment using the anti-PlGF antibody significantly improved surgical outcome by increasing bleb survival and bleb area with 29% compared to negative control (1C8). Postoperative inflammation and angiogenesis was reduced during the first days after surgery and collagen deposition was decreased at later stages. A single administration of anti-VEGF-R2 also significantly improved bleb area with 7% as compared to 1C8, but had no effect on bleb survival. Inhibition of VEGF-R2 only reduced angiogenesis and collagen deposition, but did not influence inflammation. |
| Conclusie | Targeting PlGF with an inhibitory monoclonal antibody is efficacious in improving GFS outcome, possibly even more effectively than inhibition of VEGF-R2, due to its additional effect on inflammation. These results render PlGF an appealing target for ocular wound healing and point to the potential therapeutic benefits of PlGF-inhibition. |
Auteur 1
| Naam | VAN BERGEN |
| Initialen | T |
| Instituut | KUL |
| Stad | Leuven |
Auteur 2
| Naam | Jonckx |
| Initialen | B |
| Instituut | ThromboGenics |
| Stad | Heverlee |
Auteur 3
| Naam | Hollanders |
| Initialen | K |
| Instituut | KUL |
| Stad | Leuven |
Auteur 4
| Naam | Sijnave |
| Initialen | D |
| Instituut | KUL |
| Stad | Leuven |
Auteur 5
| Naam | Van de Velde |
| Initialen | S |
| Instituut | KUL |
| Stad | Leuven |
Auteur 6
| Naam | Vandewalle |
| Initialen | E |
| Instituut | KUL |
| Stad | Leuven |
Auteur 7
| Naam | Moons |
| Initialen | L |
| Instituut | KUL |
| Stad | Leuven |
Auteur 8
| Naam | Stassen |
| Initialen | JM |
| Instituut | ThromboGenics |
| Stad | Heverlee |
Auteur 9
| Naam | Stalmans |
| Initialen | I |
| Instituut | KUL |
| Stad | Leuven |